

Western University

From the SelectedWorks of Peeyush Lala

2019

Tumor suppressor role of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in human mammary epithelial cells

Peeyush Lala, Western University



Available at: https://works.bepress.com/peeyush-lala/6/

RESEARCH ARTICLE

BMC Cancer

Open Access

Check for updates

Tumor suppressor role of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in human mammary epithelial cells

Joshua Tordjman^{1†}, Mousumi Majumder^{2†}, Mehdi Amiri¹, Asma Hasan¹, David Hess³ and Peeyush K. Lala^{1,4*}

Abstract

Background: Over-expression of cyclooxygenase (COX)-2 promotes breast cancer progression by multiple mechanisms, including induction of stem-like cells (SLC). Combined gene expression and microRNA microarray analyses of empty vector vs *COX-2*- transfected COX-2 low MCF7 breast cancer cell line identified two COX-2- upregulated microRNAs, miR-526b and miR-655, both found to be oncogenic and SLC-promoting. Cytoplasmic Polyadenylation Element-Binding Protein 2 (CPEB2) was the single common target of both microRNAs, the functions of which remain controversial. CPEB2 has multiple isoforms (A-F), and paradoxically, a high B/A ratio was reported to impart anoikis-resistance and metastatic phenotype in triple- negative breast cancer cells. We tested whether CPEB2 is a tumor suppressor in mammary epithelial cells.

Methods: We knocked-out *CPEB2* in the non-tumorigenic mammary epithelial cell line MCF10A by CRISPR/Cas9-double nickase approach, and knocked-down *CPEB2* with siRNAs in the poorly malignant MCF7 cell line, both lines being high *CPEB2*-expressing. The resultant phenotypes for oncogenity were tested in vitro for both lines and in vivo for *CPEB2KO* cells. Finally, *CPEB2* expression was compared between human breast cancer and non-tumor breast tissues.

Results: *CPEB2* (isoform A) expression was inversely correlated with *COX-2* or the above microRNAs in *COX-2*-divergent breast cancer cell lines. CPEB2KO MCF10A cells exhibited oncogenic properties including increased proliferation, migration, invasion, EMT (decreased E-Cadherin, increased Vimentin, N-Cadherin, SNAI1, and ZEB1) and SLC phenotype (increased tumorsphere formation and SLC marker-expression). Tumor-suppressor p53 protein was shown to be a novel translationally-regulated target of CPEB2, validated with polysome profiling. CPEB2KO, but not wild-type cells produced lung colonies upon intravenous injection and subcutaneous tumors and spontaneous lung metastases upon implantation at mammary sites in NOD/SCID/IL2RY-null mice, identified with HLA immunostaining. Similarly, siRNA-mediated *CPEB2* knockdown in MCF7 cells promoted oncogenic properties in vitro. Human breast cancer tissues (n = 105) revealed a lower mRNA expression for *CPEB2* isoform A and also a lower A/B isoform ratio than in non-tumour breast tissues (n = 20), suggesting that CPEB2A accounts for the tumor-suppressor functions of CPEB2.

Conclusions: CPEB2, presumably the isoform A, plays a key role in suppressing tumorigenesis in mammary epithelial cells by repressing EMT, migration, invasion, proliferation and SLC phenotype, via multiple targets, including a newly-identified translational target p53.

Keywords: CPEB2, Tumor suppressor, COX-2, EMT, EP4 receptor, Breast Cancer, Stem-like cells, MicroRNA-526b, MicroRNA-655, p53, Polysome profiling

* Correspondence: pklala@uwo.ca

⁺Joshua Tordjman and Mousumi Majumder contributed equally to this work. ¹Department of Anatomy and Cell Biology, University of Western Ontario,

London, Ontario N6A5C1, Canada

⁴Department of Oncology, University of Western Ontario, London, Ontario N6A5C1, Canada

Full list of author information is available at the end of the article



© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Content courtesy of Springer Nature, terms of use apply. Rights reserved.

Background

Upregulation of cyclooxygenase (COX)-2, an inflammationassociated enzyme, noted in half of the breast cancer patients [1] promotes tumor progression and metastasis through multiple mechanisms, including increased cancer cell proliferation, migration, invasion, epithelial-to-mesenchymal transition (EMT), tumor-associated angiogenesis, lymphangiogenesis, and induction of stem-like cells (SLCs) [2–6]. SLCs represent a dynamic state regulated by the tumor micro-environment [7] and resist chemo- and radiation therapies, causing tumor recurrence [8, 9]. COX-2 mediated stimulation of various oncogenic events in breast cancer, as listed above, is largely due to the activation of the PGE receptor EP4 by the endogenous Prostaglandin (PG)E2 [10].

Combined gene and microRNA expression microarrays with ectopic *COX-2* overexpressing and Mock (empty vector-transfected) MCF7 breast cancer cells [6] revealed 26 genes that are downregulated, along with two micro-RNAs, miR-526b [11] and miR-655 [12] that are upregulated by *COX-2*. MicroRNAs silence their gene targets either by degrading the mRNAs or blocking their translation [13]. We found that both miRNAs - miR-526b and miR-655 were oncogenic and SLC-promoting [11, 12]. The only *COX-2* down-regulated gene targeted by both microRNAs was identified as Cytoplasmic Polyadenylation Element-Binding Protein 2 (*CPEB2*), the functions of which in tumor biology remain controversial.

The CPEB family includes 4 members (CPEB1-4) which regulate translation of their target mRNAs by binding to a Cytoplasmic Polyadenylation Element (CPE) in the 3'untranslated region [14]. Polyadenylation in their target mRNAs depends on both a CPE sequence (UUUUUAAU) and a polyadenylation hexanucleotide signal (AAUAAA) [15]. CPEB proteins can repress or activate translation of target mRNAs by respectively shortening or elongating the poly-A tail [16]. CPEB1 was shown to be a tumorsuppressor, depletion of which in mammary epithelial cells led to Epithelial-Mesenchymal-Transition (EMT) and metastatic phenotype [17]. It restrained proliferation of glioblastoma cells by activating p27 mRNA reanslation [18]. CPEB3 appeared to be a tumor-suppressor, targeted by oncogenic miR-107 in hepatocellular carcinoma [19]. Furthermore, a high CPEB3 protein expression was associated with increased survival in renal cell carcinoma patients [20]. The roles of CPEB4 in tumors remain conflicting. A tumor- suppressor role was demonstrated by its being the target of an oncogenic miR-550A in hepatocellular carcinoma [21]. However, CPEB4 mediated translational activation of oncogenic mRNAs in pancreatic cancer [22], and EMT induction, growth and metastasis in gastric cancer cells [23] illustrate pro-oncogenic functions.

The role of CPEB2 in cancer remains paradoxical. A tumor-suppressor role was suggested by CPEB2 binding to HIF1 α mRNA and suppressing its translation under

normoxic conditions, but releasing it to allow translation under hypoxic conditions [24]. This results from interaction with the elongation factor eEF2 [25]. HIF1 α is short-lived under normoxic conditions, but stabilized under hypoxic conditions to stimulate genes promoting angiogenesis, EMT, migration, SLC functions, metastasis and therapeutic resistance [26]. Binding of CPEB2 to the mesenchymal transcription factor TWIST1 down-regulated its translation [27], suggesting an EMT-suppressor function. A tumorsuppressor role of CPEB2 was further suggested by its down-regulation by microRNA-885-5p, a mediator of EMT, tumorigenesis and metastasis in colorectal cancer [28].

The roles of CPEB2 in breast cancer appear to be complex, depending on the expression of different CPEB2 isoforms. CPEB2 has six isoforms (A-F). By selecting cells for anoikis-resistance in vitro from triplenegative breast cancer (TNBC) cell lines, Johnson et al. [29] reported that an alternative splicing of CPEB2, leading to a high isoform B:A ratio mediated anoikisresistance and metastatic phenotype. They suggested that isoform A which excludes exon 4 is a tumor- suppressor, whereas isoform B that includes exon 4, is a tumor-promoter. This suggestion was validated by next generation sequencing and isoform-specific downregulation of CPEB2A and B in TNBC lines [30]. They concluded that CPEB2B plays an antagonistic role against CPEB2A by alleviating the translational inhibition of HIF-1 α and Twist 1 imparted by CPEB2A.

We adopted a different approach to examine the functions of CPEB2 in breast epithelial cell lines, by depleting the entire CPEB2 gene and observing the resultant phenotypic changes: (a) CPEB2 was knocked out using a double nickase CRISPR plasmid in an immortalized non-tumorigenic human mammary epithelial cell line MCF10A, reported to be a reliable model for normal mammary epithelium [31]; (b) CPEB2 was knocked down with siRNAs in the MCF7 cell line, a mammary carcinoma of low malignancy [6]. CPEB2KO MCF10A cells exhibited an oncogenic phenotype in vitro, as indicated by increased proliferation, migration, invasion, EMT, stimulation of SLC and a downregulation of p53 tumor suppressor protein owing to a decreased translation of p53 mRNA. They exhibited lung colonization after intravenous injection and subcutaneous tumorigenicity upon inoculation at the mammary sites in NOD/SCID/ IL2Ry null mice. SiRNA-mediated CPEB2 knockdown in MCF7 breast cancer cells also resulted in enhanced oncogenic properties tested in vitro. These results confirm CPEB2 as a tumor-suppressor in breast epithelial and poorly malignant breast cancer cells likely resulting from the CPEB2A isoform prevalence in these cells. This contention was supported by a higher CPEB2A isoform expression and A: B isoform ratio in non-tumorous human breast tissues than in cancerous breast tissues.

Materials and methods

Cell culture

The immortalized non-tumorigenic mammary epithelial cell line MCF10A (ATCC, at 4–6 passages) was cultured in DMEM (Gibco, Thermofisher, CA) supplemented with 5% horse serum (Invitrogen, Thermofisher, CA), 20 ng/ml EGF, 0.5 mg/ml hydrocortisone (Sigma, Oakville, ON, CA), 100 ng/ml cholera toxin (Sigma), 10 μ g/ml insulin (Sigma), and 1% penicillin/ streptomycin (Invitrogen) [31]. MCF7 cells (ATCC, Manassas, VA, USA, at 4–6 passages) were grown in EMEM supplemented with 10% FBS, 100 μ g/mL of penicillin/streptomycin (Gibco) and 10 μ g/mL of insulin (Sigma).

CRISPR knockout of CPEB2 and SiRNA mediated CPEB2 knockdown

Total *CPEB2* was knocked out in MCF10A cells with a CRISPR double nickase plasmid (Santa Cruz, Dallas, TX, USA) targeting exon 1 of the gene, that combines a Cas9 nickase mutant with pairs of guide RNAs to introduce targeted double-strand breaks, ensuring a high knockout specificity [32]. Cells transfected with Amaxa Cell Line Nucleofector Kit IV (Lonza, Allendale, NJ, USA) were subjected to 72 h of puromycin selection and expanded. MCF7 cells were transfected with 1 μ M of either *CPEB2* siRNA (a pool of siRNAs that gave the best results) or Universal Scrambled Control siRNA (OriGene, Rock-ville, MD, USA). After 24 h media was changed and experiments conducted at 48 h. CPEB2 downregulation in KO and KD cells was validated with qRT-PCR.

Protein extraction and Western blot

Proteins extracted from cell lysates were subjected to western immunoblots [6], using primary antibodies at the following dilutions: CPEB2 (Origene cat # TA344026, rabbit polyclonal, 1:1000; lacking isoformspecificity), E-Cadherin (Cell Signalling, Danvers, Mass, USA, rabbit monoclonal, 1:1000), Vimentin (Cell Signalling, rabbit monoclonal, 1:1000), β-actin (Santa Cruz, mouse monoclonal, 1:4000 or Cell Signalling, rabbit monoclonal, 1:1000), N-Cadherin (Santa Cruz, Rabbit polyclonal, 1:400), p53 and p21 (both from Novus Biologicals, Centennial, Colorado, USA, mouse monoclonal, 1:200) and β -Catenin (Sigma, rabbit polyclonal, 1:4000). After primary antibody incubation overnight, membranes were incubated for 1 h with appropriate secondary antibody at the following dilutions: Goat Anti-Rabbit (1:10000, Li-COR, Lincoln, Nebraska, USA) and Donkey Anti-Mouse (1:10000, Li-COR). Membranes were scanned using the Odyssey Infrared Imaging System (Li-COR).

Immunofluorescence Monolayers

Cells grown on glass coverslips were treated with various primary antibodies as reported [6]: E-Cadherin (Cell Signalling, 1:500), Vimentin (Cell Signalling, 1:500), and N-Cadherin (Sigma, 1:500). The cells were then incubated with fluorochrome-conjugated secondary antibodies (Biotum, Cedarlane, Burlington, ON, CA) at the following dilutions: Goat Anti-Rabbit 594 (1:500), Goat Anti-Rabbit 488 (1:500) and Goat Anti-Mouse 488 (1:500). Vectashield anti-fade mounting medium with DAPI (Vector-labs, Burlignton, ON, CA) was used to mount the slides. Fluorescent images were taken with Zeiss LSM 510 Meta Multiphoton Confocal Microscope, and fluorescence intensities calculated with ImageJ software. The raw integrated density was calculated for each cell and normalized to the cell area. Data were presented as an average of all cells.

Tumorspheres (spheroids)

Fixation, permeabilization, and antibody staining for tumorspheres (minimum $60 \,\mu\text{m}$ diameter) were conducted as reported [6]. Incidence of fluorescent cells (for ALDH1, NANOG, and SOX-2) was computed among total number of cells marked by DAPI.

Migration and invasion assays using Transwells

Semi-confluent MCF10A and MCF7 cells were serumstarved overnight and seeded on microporous membranes (8 μ m pore diameter) coated without or with Matrigel respectively for migration and invasion assays using transwell inserts [6]. Bottom chambers included 5% horse serum to stimulate migration or invasion respectively for 24 and 48 h. The cells at the bottom of the membranes were fixed with cold methanol, stained with Eosin (cytoplasm) and Thiazine (nucleus), and mounted onto glass chamber slides to count all cells. Assays were done in triplicate.

Migration (wound-healing) assays using scratch method

Cells grown to semi-confluency were serum-starved over-night. Proliferation inhibitor mitomycin C $(1 \text{ ng}/\mu l)$ was added 2 h before the plate was scratched with a microtip. Cells were then incubated in medium including 1% horse serum and mitomycin C for 72 h, replacing media every 24 h. Migration, un-affected by proliferation was measured as the distance covered per unit time.

Zymography

Cell-free conditioned media were collected at 24 h and frozen at – 20 °C. 10% zymogram gels were made with Gelatin A to measure gelatinolytic activity. Conditioned medium mixed 1:1 with zymogram sample buffer, was loaded and run at 110 V for 90 min. The gel was incubated in zymogram renaturation buffer for 1 h, then in zymogram developing buffer for 1 h, and finally overnight at 37 $^{\circ}$ C in fresh zymogram developing buffer (all from BioRad, Mississauga, ON). Gels stained with Coomassie Blue were imaged using the BioRad XR+ Gel documentation system.

Tumorsphere (spheroid) formation assay

MCF7 and MCF10A cells were grown as spheroids on ultra-low attachment plates as reported [6]. In brief, cells grown to 70-80% confluency were trypsinized and spun down. They were then suspended in basal HuMEC media (Gibco) with added B-27 supplement (Gibco), EGF (20 ng/mL, Invitrogen) and FGF (20 ng/mL, Invitrogen), taken up by a 1 mL syringe and put through a 40 µm cell strainer (Falcon) to collect a single cell suspension. The cells were then counted and seeded at a density of 10 cells/well in an ultra-low attachment 96-well plate (Thermo Fisher) to measure spheroid forming efficiency (SFE), as well as 1×10^3 cells/well in an ultra-low attachment 6-well plate (Corning, NY, USA) for for RNA analysis and immunofluorescence. SFE was calculated at 4 days as the total number of spheroids (minimum 60 µm in diameter) divided by total number of cells plated.

Polysome profiling

Polysome profiling was performed as reported [33]. WT or CBEB2KO MCF10A cells were pre-treated with cycloheximide (CHX, 100 µg/mL) for 5 min at 37 °C. Cells were washed twice with ice-cold PBS containing 100 µg/mL CHX and lysed in hypotonic buffer (100 mM KCl, 50 mM Tris-HCl pH 7.4, 1.5 mM MgCl2, 1 mM DTT, 1 mg/mL heparin, 1.5% NP40, 100 µg/mL CHX, supplemented with mini cOmplete[™] Protease Inhibitor Cocktail tablet and 100 Unit RiboLock RNase inhibitor). The lysates were incubated on ice for 5 min and cleared by centrifugation at 12000 rpm for 5 min at 4 °C, prior to loading on 10-50% sucrose gradients to isolate the sub-polysomal and polysomal fractions. Total RNA was isolated from each fraction using Trizol reagent and converted to cDNA using Super-Script III First-Strand Synthesis System (Life Technologies, Burlington, ON). RT-PCR was performed for each gene using a PCR thermocycler (Bio-Rad) and visualized by agarose gel electrophoresis.

Cell proliferation assays

WT or CPEB2KO MCF10A cells were incubated for 24 h in complete media with or without EDU (negative control for autofluorescence) using Click-iT EdU Alexa Fluor 488 Imaging kit (Invitrogen). EdU incorporation was measured in an analytical flow cytometer. BrdU incorporation was measured in WT, MOCK and CPEB2KD MCF7 cells using the Cell Proliferation ELISA, BrdU (colorimetric) Kit (Roche, Sigma) and an Epoch Microplate Spectrophotometer at a wavelength of 370 nm with a reference wavelength of 492 nm.

Animal experiments for tumorigenicity assays

NOD/SCID/IL2Ry-null (NSG) mice (deficient in T, B and NK cells) were bred locally by Dr. David Hess (coauthor) and maintained according to the Canadian Council of Animal Care guidelines with food and water ad libitum at the Robarts Research Institute mouse barrier. The protocol was approved by the Animal Care and Veterinary Services (ACVS) committee on animal use. Six-week-old females were used as hosts for tumorigenicity assays by intravenous or subcutaneous routes using 5×10^5 CPEB2KO and WT MCF10A cells per mouse. They were euthanized with CO_2 at the appropriated time. Tail vein injected mice (n = 6) were sacrificed at 8 weeks to isolate lungs, spleen and liver to assess metastases. Cells mixed 1:1 with Matrigel were injected S.C. into both right and left inguinal mammary regions of 5 mice each for CPEB2KO or parental cells (total = 10 sites each). After 12 weeks at sacrifice, one mammary fat pad was stored in O.C.T. for frozen sectioning and the other in Bouin's solution for paraffin embedding. Lungs, liver and spleen were also harvested to assess spontaneous metastasis from mammary sites. All lungs were inflated with PBS prior to isolation. All mice were weighed once per week.

Tissue processing from mice

Lungs, liver and spleen were stored either in O.C.T for cryosectioning or Bouin's solution/Neutral-Buffered Formalin for fixation and paraffin embedding. Paraffin blocks were sectioned at 5 µm and stained with H&E. Frozen organs were sectioned at 8 µm for lungs, liver and spleen, while mammary fat pads were sectioned at 10 µm. Sections were then fixed in 10% formalin, permeablized in 0.1% Triton-X-100, and blocked with M.O.M (mouse-on-mouse Ig, Vector labs, Burlington, ON) prior to immuno-staining. Mouse anti-HLA antibody (1:100, BD, Mississauga, ON), followed by horse anti-mouse FITC (1:200, Vector Labs) was applied to detect human cells. Sections were mounted with Vectashield (Vector Labs), stained with DAPI and viewed under a fluorescent microscope. Micrometastases were arbitrarily scored as single cells, clusters (2-8 cells) and colonies (>8 cells) as reported earlier [6] and averaged within 3 sections, 5 images of 1600µm² each per section.

Measurements of CPEB2 expression in human breast cancer cell lines, breast cancer and non-tumor breast tissues

Using the blast search, we found that primers used by Johnson et al. [29] for CPEB2A covered all 6 isoforms, whereas primers used for CPEB2B covered both isoforms B and D. In our study we used probes with increased isoform specificity: a Taqman probe for isoform A/E and another probe for isoform B/D (Applied Biosystems, ThermoFisher) to conduct qPCR in a panel of human breast cancer tissues (n = 105) and non-tumor breast tissues (n = 20) obtained

from the Ontario Tumor bank (OTB) maintained by the Ontario Institute of Cancer Research (OICR) following ethics approval by the OICR committee. This bank receives tumor tissues from donors in Ontario hospitals following donor consent. Taqman probes (Applied Biosystems) for GAPDH and β -Actin were used as the internal loading control. Delta Ct values were calculated by subtracting the average Ct values (triplicate) from the control and analyzed as previously described [6].

The probe for isoform A/E was also utilized to compare *CPEB2A* expression in a panel of *COX-2* disparate human breast cancer cell lines MCF7, MCF7-COX2, MDA-MB-231 and SKBR3. To conduct qPCR for *CPEB2* in MCF7 cells we used a Taqman probe from Life Sciences, which is not isoform-specific. To conduct RT-PCR for *CPEB2* in MCF10A cells, we designed oligos to cover all isoforms: Forward: ACACTCTTACCCTTA-CAGGTG; Reverse: CGCCCATAACTCCTTGCATT.

Statistical analysis

Statistical analyses were performed using Graphpad Prism Software 5.0 (Graphpad Software Inc. 2007). All parametric data were analyzed with one-way ANOVA followed by Tukey-Kramer or Dunnett's post hoc comparisons. Spheroid and lung colony numbers were analyzed both by parametric and non-parametric (Mann-Whitney test) methods, giving similar results. Student's t test was used to compare two datasets. Statistically relevant differences between means were accepted at p < 0.05.

Results

CPEB2 is the single COX-2 down-regulated gene targeted by miR-526b and miR-655

We found that miR-526b and miR-655 collectively targeted a total of 13 *COX-2* -down-regulated genes, 12 of which are tumor-suppressor-like. The remaining single gene targeted by both microRNAs was identified as *CPEB2* (Additional file 4: Table S1).

CPEB2 expression levels in multiple breast cancer cell lines

CPEB2 mRNA expression (of the A/E isoform) compared in multiple *COX-2* divergent cell lines (Fig. 1a) shows an approximately inverse relationship with *COX-2* and the miR-526b and miR-655 expression levels. Similarly CPEB2 protein levels (measured in western blots with an isoform-non-selective antibody, that produced a single band of putative isoform A (approx. 60 kDa) were higher in *COX-2*-low (MCF7, T47D) than in *COX-2*high (MDA-MB-231, HS578T) cells (Fig. 1b).

Validation of CPEB2 down-regulation in CPEB2KO MCF10A cells and CPEB2KD MCF7 cells

CPEBE2 mRNA and protein levels were very high in MCF10A cells, in which we knocked-out CPEB2 (inclusive of all isoforms) using a double nickase CRISPR plasmid to ensure high specificity. A comparison of mRNA and protein levels in WT and KO cells (Fig. 1c) demonstrated approximately 80% knock-out efficiency (Fig. 1d). PCR data revealed a single band corresponding to isoform A, both in WT and CPEB2KO MCF10A cells confirming that MCF10A cells lack in the B isoform [29]. We also knocked down CPEB2 in the poorly malignant, CPEB2A dominant breast cancer cell line MCF7, using a pool of siRNAs. Scrambled siRNAs served as controls (Mock cells). An efficient knock-down (approximately 75% relative to WT or Mock cells) was noted at the mRNA level (agarose gel picture in Fig. 1e; quantification of Fig. 1e presented in Fig. 1f).

CPEB2 downregulation in breast epithelial cells induces EMT and promotes migration and invasion

Upon CPEB2 knock-out, the epithelial-like (polygonal shaped) wild-type MCF10A cells (Fig. 2a) assumed a mesenchymal-like (spindle-shaped) morphology (Fig. 2b). To test an association of this morphological change with EMT, we compared EMT markers in WT and CPEB2KO cells using qRT-PCR and Western blots. mRNA expression for the epithelial marker CDH1 (E-Cadherin, a transmembrane protein) was suppressed, with a concomitant increase in mesenchymal markers VIM (Vimentin, an intermediate filament) and two transcription factors SNAI1 and ZEB1 (Fig. 2c). Western blots revealed a near-complete depletion of E-Cadherin and increases in mesenchymal markers N-Cadherin and Vimentin proteins (Fig. 2d and e). Cellular immunofluorescence for the respective proteins corroborated this phenotype of reduced E-Cadherin, increased N-Cadherin and Vimentin (Figs. 2g showing morphology, and 2F quantitation). Similarly, CPEB2KD MCF7 cells also displayed EMT phenotype, as illustrated by a significant downregulation of E-Cadherin and upregulation of Vimentin and TWIST proteins relative to WT or Mock-transfected MCF7 cells, identified with immunofluorescence and Western blots (Additional file 1: Figure S1).

EMT is a functional associate of cellular migratory and invasive abilities due to changes in molecular expression profiles. For example, loss of E-Cadherin emancipates cells from contact inhibition [34, 35], whereas an increase in Vimentin mediates cytoskeletal reorganization needed for motility [36]. To assess changes in migration alone independent of proliferation, cells were serumstarved overnight and incubated with mitomycin C prior to scratching (or wound-healing) assay. CPEB2KO cells migrated at a significantly faster rate than wild-type cells



Fig. 1 CPEBZA expression in Various un-manipulated and manipulated cell lines. **a** COX-2, miR-52.6b and CPEBZA were quantified in different (COX-2 disparate) breast cancer cell lines, relative to MCF7 cells. Cell lines (MDA-MB-231 and MCF7-COX-2) with high COX-2 and miRNAs expression showed low expression of *CPEBZA* (measured with an A/E probe). **b** Western blots for CPEB2 protein (about 60 kDa, presumably CPEB2 A, identified with an isoform nonselective antibody) revealed a similar trend, high expression of CPEB2 in poorly malignant, low COX-2 expressing MCF7 and T47D cells, and low expression in high COX-2 expressing and metastatic MDA-MB-231 and Hs578T cells. **c**, **d** CPEB2 knockout (KO) through a double nickase CRISPR plasmid in MCF10A cells resulted in downregulation of CPEB2 mRNA (shown with RT-PCR) and protein (shown with Western blot). CPEB2 protein expression was knocked out with 80% efficiency. **e**, **f**. SiRNA-mediated knockdown of *CPEB2* mRNA using a pool of siRNAs in MCF7 cells shows 75% downregulation. Data presented as mean of 3 replicates ± SEM. (*) indicates p < 0.05, (**) p < 0.001, (***) p < 0.0002

during 72 h (Fig. 3a and b). By 24 h, the migration was 10-fold faster.

Migration was also measured in transwells (chemokinesis assay), in which serum-starved cells were allowed to migrate through microporous membranes for 24 h into a medium containing 5% Horse Serum. CPEB2KO cells migrated faster than WT cells (Fig. 3c). Similarly, CPEB2KD MCF7 cells also migrated faster than the Mock (scrambled siRNA-transfected) or WT MCF7 cells (Additional file 2: Figure S2A).

Ability to invade basement membrane components is an important prerequisite for metastasis. Invasion was measured as above for 48 h, in which the microporous membranes were coated with a basement membrane analog Matrigel. CPEB2KO MCF10A cells exhibited a higher invasive ability than WT cells (Fig. 3d). CPEB2KD MCF7 cells also showed significantly higher invasiveness than Mock or WT MCF7 cells (Additional file 2: Figure S2B). Increased matrix-degrading ability of CPEB2KO MCF10A cells was corroborated by gelatin zymography, showing a 2.9 fold increase in gelatinase A (MMP-9) activity (Fig. 3h).

CPEB2KO promotes proliferation

Sustained proliferative ability is a hallmark of cancer cells [37]. Flow cytometry for 5'- ethynyl-2'-deoxyuridine (EdU) incorporation (measuring DNA synthesis) for 24 h revealed a four-fold increase in CPEB2KO MCF10A cells compared to WT cells (Fig. 3e and f) in 3 replicate preparations. CPEB2KD MCF7cells, however, exhibited only a minor



increase (p = 0.06) in proliferative ability compared to mock cells (Additional file 2: Figure S2C).

P53 translation is repressed in CPEB2-KO cells

CPEB1 and CPEB2 were reported to co-regulate two transcription factors HIF1 α [24] and TWIST1 [27]. CPEB1 was also shown to be a translational regulator of p53, a powerful tumor- suppressor. *P53* mRNA contains 2 CPE domains in its 3' UTR, which promote polyade-nylation. In CPEB1 knock-down cells, *p53* mRNA had an abnormally short poly (A) tail reducing translational efficiency and a marked decrease in p53 protein [38]. Hence using CPEB2KO MCF10A cells we examined

whether p53 is a candidate translational target of CPEB2. qRT-PCR revealed no significant difference in *p53* mRNA expression between CPEB2KO and WT cells (Fig. 4a). However, p53 protein levels measured with western blot, revealed ~60% reduction (Fig. 4b and c), suggesting that p53 is differentially regulated at the translational level. We also examined expression of p21 protein, a downstream effector of p53, using western blot and found a 66% reduction in the CPEB2KO cells (Fig. 4d and g), indicating that the p53 pathway is negatively affected.

To interrogate whether p53 protein was translationally regulated by CPEB2, we compared polysome profiling



MCF10A cells that were scratched and allowed to migrate in 1% Horse Serum, in the presence of mitomycin C to block proliferation. **b** Cell migration rate was measured as (distance at 0 h – distance at 24 h or 48 h or 72 h). WT cells migrated in a rate of 3.57 μ m/day, whereas CPEB2KO cells migrated 35.82 μ m/day. Scale = 100 μ m. **c** Migration and (**d**) invasion of WT and CPEB2KO MCF10A cells in transwell chambers. Serum starved cells were allowed to migrate/invade in the presence of 5% Horse Serum in the bottom chamber. Cells were treated with Mitomycin C to block proliferation. The migration rate was 10.89 fold and invasion 3.43 fold in CPEB2KO cells relative to WT cells. **e**, **f** Proliferation (24 h EdU uptake measured with flow cytometry for immune-fluorescence) showing about 4 fold increase in CPEB2KO cells relative to WT cells in a representative assay. **g** Data presented as mean normalised % difference in proliferation between KO and WT cells (KO-WT)/WT. **h** Gelatinase A (MMP9) activity in WT and CPEB2KO MCF10A cells measured with densitometry of zymograms, WT cells normalised to 1. Quantitative data presented as mean of 3 ± SEM. (*) indicates p < 0.05, (**) p < 0.001, (***) p < 0.0005

between WT and CPEB2KO MCF10A cells. The profile appeared almost identical indicating no significant difference in global translation between the two cell types (Fig. 4e). RT-PCR was performed to evaluate the distribution of β -actin and p53 mRNAs across a sucrose density gradient. While β -actin distributions were similar in both cells, p53 mRNA was significantly shifted toward light polysomes in CPEB2KO cells (Fig. 4f). These results, combined with the findings of the absence of any change in p53 mRNA in CPEB2KO cells, clearly reveal that CPEB2 knock-out decreased the translation of p53 by shortening the Poly A tail leading to decreased p53 protein.

CPEB2KO/KD stimulates SLC phenotype

CPEB2 being a common target of both SLC-promoting miRNAs, we examined whether *CPEB2* downregulation in MCF10A and MCF7 cells stimulated SLC properties using the spheroid (tumorsphere) formation assay which measures the ability of single cells to self-renew in an anchorage-independent manner when grown on ultralow attachment plates [6]. CPEB2KO MCF10A cells displayed significantly increased spheroid formation (morphology shown in Fig. 5a) and spheroid forming efficiency (SFE, shown in Fig. 5b) as well as growth rate of spheroids (indicated by the spheroid size) on day 4, compared to WT cells (Fig. 5 C). CPEB2KD MCF7 cells



Fig. 4 Translational regulation of p53 in CPEB2KO cells. **a)**qRT-PCR for p53 mRNA expression showing no difference between WT and CPEB2KO cells. **b** Western Blots for p53 and (**c**) quantification of western blots showing p53 protein expression was significantly reduced (to 0.41) in CPEB2KO cells. **d**, **g** p21 (downstream effector of p53) protein expression was significantly reduced (to 0.34) in CPEB2KO compared to WT cells. Western blot presented in (**d**) and quantitation in (**g**). Data represent mean of 3 replicates \pm SEM. (**) indicates p < 0.001, (***) p < 0.0001. **e** Polysomal profiles of global protein translation in WT and CPEB2KO MCF10A cells showing no difference. **f** RT-PCR was performed to evaluate the distribution across a sucrose density gradient of ACTB and p53 mRNAs, showing that p53 mRNA was significantly shifted toward light polysomes in CPEB2KO cells

also displayed significant increase in spheroid formation (morphology shown in Fig. 5d and SFE in Fig. 5e).

Wnt/ β -Catenin signaling is a well-known pathway used by cancer cells for multiple malignancy-associated functions including SLC properties [39], as demonstrated in *COX-2* over-expressing breast cancer cells [6]. CPEB2 was reported to bind β -Catenin mRNA to repress translation in mouse neuronal cells [40]. Therefore we compared the levels of β -Catenin protein in WT and CPEB2KO MCF10A cells, as well as changes in the expression of genes (*AXIN2, AXIN1, CCND1, cMyc*) downstream in the canonical Wnt/ β -Catenin pathway. Western blot for β -Catenin protein revealed an increase in CPEB2 KO compared to WT cells (Fig. 5g and h). This was associated with significant increases in *CCND1* and *AXIN1* mRNAs (Fig. 5f), suggesting that Wnt/ β -Catenin pathway may be involved in SLC stimulation noted earlier. We also immuno-stained spheroids for certain SLC-associated markers, as reported earlier [6]. CPEB2KD MCF7 cells showed significantly increased incidence of cells expressing SOX2, NANOG and ALDH1, compared to control mock-transfected MCF7 cells (Fig. 6).

CPEB2KO MCF10A cells reveal an upregulation of VEGF-D, COX-2 and EP4

We reported that ectopic *COX-2* over-expressing MCF7 cells displayed an upregulation of VEGF-A, VEGF-D and EP4 receptor [6]. Furthermore two COX-2-upregulated miRNAs miR-526b and miR-655, which target *CPEB2*, when ectopically over-expressed in miRNA-low MCF7 cells led to an upregulation of EP4 and COX-2, indicating a positive feed-back loop for pathways in SLC



Fig. 5 Increased spheroid formation by CPED2-KO and CPED2-KD cells. **a** Representative images of spheroids (scale = 60 µm) and **(b**) spheroid forming efficiency (SFE) of WT and CPEB2KO MCF10A cells grown on ultra-low attachment plates for 4 days. SFE is computed as the number of spheroids (> 60 µm) divided by total number of cells plated. CPEB2KO cells showed 5.12-fold increase in SFE (p < 0.001). **c** Dot plot of spheroid size (Mann-Whitney Test for statistical significance) showing increased average diameter (WT = 70.92 µm, CPEB2KO = 91.42 µm; p < 0.0005), indicating enhanced spheroid growth rate. **d** Images of spheroids and (**e**) SFE in Mock and CBEB2-KD MCF7 cells, showing an increase in CPEB2-KD cells. **h** Representative Western blot and (**g**) quantification (Mean of 3 ± SEM) of β- Catenin protein expression. **f** qRT-PCR (Mean of 3 ± SEM) for downstream genes of β-Catenin pathway. β-Catenin was increased 1.29 fold (p = 0.048) in CPEB2KO cells, with increases in downstream target genes CCND1 (3.49 fold, p = 0.039), and AXIN1 (1.298 fold, p = 0.034). No significant change was observed in AXIN2 (1.73 fold change, p = 0.10) or Myc (0.76 fold change, p = 0.051)

sustenance [11, 12]. These findings prompted us measure *VEGF, EP4* and *COX-2* mRNAs in CPEB2KO MCF10A cells. We found a significant upregulation of *VEGF-D, COX-2* and *EP4* mRNAs (Additional file 3: Figure S3). Conversely, inhibition of COX-2 or EP4 activity in MCF7-COX2 cells which was found to suppress SLC activity [6] also upregulated *CPEB2* (data not presented).

CPEB2KO MCF10A cells form tumors in immunecompromised mice

Using NOD/SCID/IL2RY-null mice, we confirmed the findings that wildtype MCF10A cells, although immortalized, are epithelial in nature and non-tumorigenic [31, 41]. Intravenous inoculation of WT cells resulted in no identifiable lung colonization by gross or histological examination (H &E staining) or staining for HLA at 8 weeks. However, CPEB2KO cells formed micro-metastasis-like lesions in the lungs identified with H&E staining and staining for HLA (Fig. 7a), which could identify single cells, clusters and colonies. Quantitative data at 8 weeks are provided in Fig. 7b. Furthermore, macroscopic tumours at the mammary sites (illustrated in Fig. 7d) were noted after subcutaneous injection of the CPEB2KO cells in all mice at 9 out of 10 injection sites, but none with wild-type cells, validated with immunostaining for HLA at 12 weeks (illustrated in Fig. 7c). At 12 weeks, some of the former mice (2 out of 5) displayed spontaneous metastases to the lungs, identified with the HLA marker. Average incidence per lung sections was $(400 \,\mu\text{m})^2$ was: CPEB2KO-1: 15 +/-2 single cells, 10+/-2 Clusters, and 4+/-1 colonies; CPEBE2 KO-2: 12+/-2 single cells, 8+/



-2 clusters and 3+/-1 colonies. None of the mice injected with WT cells displayed any lung metastasis.

CPEB2 isoforms a and B expression in human breast cancer tissues

An examination of *CPEB2* expression in TNBC was reported be isoform-selective, having increased B/A ratio [29]. We examined the expression of CPEB2 isoforms A (indistinguishable from E, by the available probe) and B (indistinguishable from D, by the available probe) in 105 breast cancer and 20 histologically confirmed non-tumour breast tissues (Fig. 8). Compared to non-tumor breast tissues, cancerous tissues exhibited a lower expression of isoform A and a higher expression of isoform B, as indicated by Δ CT, lower values indicating higher expression. The ratio of A/B isoforms (ratios of mean of Δ CT) was higher in non-tumor tissues (Fig. 8a), supporting the reports that A is the tumor-suppressor isoform and B the tumor-promoter isoform [29, 30]. The information on ER, PR and HER2 status (n value) was available in 98 out of 105 samples as follows: 19 HER2+, 64 HER2-, 75 ER+, 18 ER-, 64 PR+, 29 PR-, 11 ER/PR/HER+ and 10 ER/PR/HER2-. A comparison of CPEB2A and CPEB2B expression in different tumor subsets revealed no significant difference in any subset in our samples (Fig. 8b).

Discussion

The roles of CPEB2 in human breast tumorigenesis have so far remained a paradox, until isoform-specific roles were identified [29, 30]. Selecting cells from TNBC cell lines for anioikosis-resistance, these authors observed that alternative splicing resulting in the loss of CPEB2A with concomitant increase in CPEB2B was responsible for their metastatic phenotype. CPEB2 was shown to suppress the translation of two oncogenic transcription factors, TWIST1 [27] - an EMT inducer, and HIF1 α [24] associated with many oncogenic functions [24, 25]. Deligio et al. [30] reported that anoikosis-resistance and metastasis phenotype of TNBC cell lines resulted from CPEB2B isoform mediated translational activation of HIF1 α and TWIST1. They suggested that CPEB2B plays



an antagonistic role against CPEB2A by alleviating the translational inhibition of HIF1 α and TWIST1 imparted by CPEB2A.

In the present study, by depleting the entire *CPEB2* gene, we demonstrated a robust role of *CPEB2* in suppressing a variety of oncogenic functions in both MCF10A and MCF7 cell lines, evidently due to the CPEB2A isoform, prevalent in both cell lines. Reportedly, no alternative splicing of CPEB2 or presence of isoform B was detectable MCF10A cell line [29]. In both cell lines, we found that *CPEB2* downregulation promoted EMT, proliferation, migratory and invasive functions, as well as SLC phenotype measured with spheroid-forming ability. The spheroids formed by CPEB2KO MCF10A cells exhibited a higher growth rate, indicating a faster self-renewal of the SLC population. Increased β -Catenin protein noted in CPEB2KO cells may be responsible for a higher self-renewal capacity of stem-like cells or increased proliferative ability of non-stem cells. For example, increased β -Catenin signaling can lead to increased expression of *CCND1*, a nuclear protein, that forms a complex with CDK4 and CDK6 leading to progression of cells from G1 into S-phase [42].



During EMT, polar epithelial cells assume an elongated nonpolar mesenchymal morphology, associated with an acquisition of mesenchymal cell markers, increased migratory ability, cell survival, and invasiveness [43]. E-Cadherin, an epithelial cell junction-associated protein mediates cell-cell adhesions, contact inhibition and control of cell proliferation [34]. It is lost during EMT [35], as shown with CPEB2KO or KD cells. However, EMT also requires "Cadherin switching" in which expression of E-Cadherin is exchanged for other cadherins, such as N-Cadherin [44, 45]. Ectopic overexpression of N-Cadherin in MCF7 cells stimulated migration and invasiveness through upregulation of MMP-9 and metastasis [46]. Here, in CPEB2KO MCF10A cells, a switch from E-Cadherin to N-Cadherin was clearly evident. Increased MMP-9 activity shown with gelatin zymography explained their increased invasive capacity. While transcriptional regulation of N-Cadherin during cadherin switching is unknown, Twist1 can modulate N-Cadherin expression by binding to the E-box on CDH2 (N-Cadherin) [45, 47].

Numerous transcription factors may have contributed to the EMT phenotype in CPEB2KO cells. TWIST1 can mediate EMT [48], and also inhibit apoptosis through evasion of p53-induced cell death [49]. CPEB2 mediated translational repression of TWIST1, a function ascribed to the A isoform [30] could be a mechanism by which EMT is suppressed. In support, in CPEB2KO cells exhibited no change in *TWIST1* mRNA expression, suggesting posttranscriptional regulation by CPEB2. An increase in *SNAI1* and *ZEB1*, observed in CPEB2KO cells, could additionally contribute to EMT. Both molecules are known to suppress transcription of E-Cadherin and play important roles in invasion and metastasis [50, 51].

P53 is a master tumour-suppressor, responsible for suppressing EMT, migration, and invasion through transcriptional regulation of many other molecules [52]. Here, we show for the first time that CPEB2 is a novel translational regulator of *p53*, as was reported for CPEB1 [38]. Polysome profiling confirmed that a reduction in p53 protein in CBEB2KO cells is due to reduced *p53* mRNA translation resulting from shortened Poly A tail, rather than an

indirect mechanism by binding to another target molecule. Additionally, another tumor suppressor protein p21, a downstream partner of p53 was also reduced in CPEB2 KO cells.

We have shown that ectopic COX-2 overexpression in MCF7 cells promoted SLC phenotype associated with increased expression of EP4 receptor, Notch and *Wnt* [6]. Wnt pathway protein β -Catenin and the downstream Wnt pathway genes CCND1, AXIN1 and AXIN2 were all significantly upregulated in MCF7-COX2 spheroids [6]. In the present study CPEB2KO cells exhibited an upregulation of β-Catenin protein, AXIN1 gene, and interestingly also COX-2 and EP4 genes linking with SLC phenotype [6]. It is likely that an upregulation of COX-2/EP4 provided a positive feed-back loop for SLC sustenance in CPEB2KO cells, as shown for miR-526-B and miR-655 overexpressing cells [11, 12]. Conversely, treating MCF7-COX2 cells with either a COX-2 inhibitor celecoxib or with an EP4 antagonist ONO-AE3-208 significantly up-regulated CPEB2 in these cells (data not presented), concomitant with a marked drop in their spheroid-forming capacity [6]. The molecular mechanisms underlying this CPEB2-COX2/EP4 regulatory loop remains to be investigated. One possible pathway is binding of CPEB2 to HIF-1α [24], a known upregulator of COX-2. Furthermore, increased β-Catenin protein noted in CPEB2KO cells can stabilize COX2 mRNA by interacting with AU-rich elements of 3'-UTR [53]. Collectively, the SLC stimulation in CPEB2KO MCF10A cells could be due to an upregulation of COX2/EP4, and Wnt pathway genes.

Finally an examination of breast cancer and nontumor breast tissues revealed a lower expression CPEB2 isoform A and higher expression of isoform B in cancerous tissues. This difference was more evident by measuring the ratios of A: B isoforms, presented in Fig. 8a. These results are in concordance with reported tumorsuppressor vs tumor-promoter functions of A and B isoforms [30]. However our probes could not demonstrate a preferential expression of A (A/E) or B (B/D) isoform in any of the tumor subsets based on the information on their ER, PR or HER2 status. Since these samples contained variable proportion of stromal and immune cells, it is possible that they may have masked the differences.

In summary, we demonstrate here that CPEB2, presumably the isoform A, plays a significant role in suppressing tumorigenesis in mammary epithelial cells by repressing EMT, migration, invasion, proliferation and SLC phenotype, possibly through multiple targets, one of them identified here as p53. Figure 8c presents a schema for the proposed mechanisms in tumor suppressor functions of CPEBE2.

Conclusions

Present study, utilizing in vitro and in vivo functional assays in *CPEB2*-depleted mammary epithelial cells as well as human breast-derived non-tumor and cancerous tissues, demonstrates that CPEB2, presumably the isoform A, plays a key role in suppressing tumorigenesis in mammary epithelial cells. The underlying mechanisms involved suppression of EMT, migration, invasion, proliferation and SLC phenotype, via a newly-identified translational target p53.

Additional files

Additional file 1: Figure S1. EMT marker proteins identified in MOCK and CPEB2KD MCF7 cells. Top panel: (A) and (B). Immunofluorescence Images for E-Cadherin and Twist 1 (stained green), nuclei stained blue with DAPI. CPEBKD cells show decreased E-Cadherin on cell membranes, and increased Twist 1 in cytoplasm. Bottom panel: Left, (C) and (D): Quantification of fluorescence (normalized to 1 for control mock cells showing significant reduction of E-Cadherin and increase in Twist 1 in KD cells (p < 0.05). Right, (E) Western blots showing decreased E-Cadherin and increased Twist 1, and a very minor increase (not significant) in Vimentin. (JPG 173 kb)

Additional file 2: Figure S2. Migration, invasion and proliferation in MCF7 cells after CPEB2KD. **(A)** Migration and **(B)** invasion measured in transwells respectively at 24 and 48 h reveal significant increases in CPEB2KD cells (p < 0.05). **(C)** Proliferation measured with 24 h BrdU uptake showed a minor increase, not significant (p = 0.06). Data represent means of 3 replicates (±SEM). (JPG 78 kb)

Additional file 3: Figure S3. VEGF-D, COX-2 (*PTGS2*) and EP4 (*PTGER4*) expression in MCF10A cells. Expression of mRNA (qRT-PCR; Mean \pm SEM) for VEGF, COX-2 and EP4 in WT and CPEB2KO cells (n = 3). No change was seen in the expression of *VEGFB* or *VEGF-C*, however a 4.68-fold up-regulation of *VEGF-D* was seen in the CPEB2KO cells compared to WT cells (p = 0.0020). *COX-2* mRNA expression increased 4.31-fold (p = 0.0024) and EP4 mRNA expression increased 3.45-fold (p = 0.011) compared to WT cells. (*) indicates p < 0.05. (**) indicates p < 0.05.

Additional file 4: Table S1. Differential gene and microRNA microarrays conducted with MCF7 and MCF7-COX-2 cells identified two COX-2 up-regulated miRNAs miR526b and miR655. They collectively target 13 COX-2 downregulated genes, of which *CPEB2* appeared as the single common target. (DOCX 17 kb)

Abbreviations

ALDH: Aldehyde Dehydrogenase; ANOVA: Analysis of Variance; ATCC: American Type Culture Collection; CCND1: Cyclin D1; CDH1: Ecadherin; CDH2: N-cadherin; CDK4/6: Cyclin Dependent Kinase 4/6; COX: Cyclo-oxygenase; CPE: Cytoplasmic Polyadenylation Element; CPEB: Cytoplasmic Polyadenylation Element Binding Protein; CPEB2KD: CPEB-2 Knockdown; CPEB2KO: CPEB-2 Knockout; CRISPR: Clustered Regularly Interspaced Short Palindromic Repeats; Ct: Threshold Cycle; DAPI: 4',6-Diamidino-2-Phenylindole; DMEM: Dulbecco's Modified Eagle Medium; EdU: 5'-ethynyl-2'-deoxyuridine; eEF2: Eukaryotic Elongation Factor 2; ELISA: Enzyme-Linked Immunosorbent Assay; EMT: Epithelial-to-Mesenchymal Transition; EP: Prostaglandin E Receptor; GAPDH: Glyceraldehyde 3-Phosphate Dehydrogenase; H&E: Hematoxylin & Eosin; HER2: Human Epidermal growth factor Receptor 2; HIF-1a: Hypoxia Inducible Factor 1a; HLA: Human Leukocyte Antigen; HS: Horse Serum; IL2RY: Interleukin 2 Receptor Υ chain; MCF: Michigan Cancer Foundation; MMP: Matrix Metalloproteinase; NOD: Non-Obese Diabetic; PG: Prostaglandin; qRT-PCR: Quantitative Reverse Transcription Polymerase Chain Reaction; SEM: Standard Error of the Mean; siRNA: Small Interfering RNA; SLC: Stem-Like Cells; TNBC: Triple Negative Breast Cancer; UTR: Untranslated Region; VEGF: Vascular Endothelial Growth Factor; ZEB1/2: Zinc-finger E-Box-Binding

Acknowledgements

We thank Dr. Trevor Shephard (Departments of Anatomy and Cell Biology, and Obstetrics & Gynecology, University of Western Ontario) for his expert advice on the CRISPR/Cas9-double nickase method.

ARRIVE guidelines/methodology

We have adhered to the ARRIVE guidelines/methodology.

Authors' contributions

All authors made substantial contributions, as follows. JT conducted the experiments related to MCF10A cells (presented in his Master's thesis), and wrote the first draft; MM performed the experiments with human tissues, analyzed the data and revised manuscript draft; MA performed and analyzed the polysomal profiling; AH conducted experiments related to MCF7 cells (presented in her Master's thesis); DH bred and provided the NSG mice, supervised tumor transplantation and staining for HLA; checked the results on tumorigenicity; PKL directed and supervised the overall study and wrote the final draft of the manuscript. All authors approved the final submitted version of the manuscript and ensured the accuracy.

Funding

The study was supported by funds of the Ontario Institute of Cancer Research (OICR) and Natural Sciences and Engineering Research Council of Canada (NSERC) to PKL, and NSERC to MM. AH was a scholar of the Translational Breast Cancer Research Unit, with funds derived from the Breast Cancer Society of Canada. The funders had no role in the studies.

Availability of data and materials

All data are included in this manuscript including Additional files.

Ethics approval and consent to participate

Animal were used according the guidelines of the Canadian Council of Animal care, and experimental protocols approved by the ACVS committee. Human tissues were obtained from the Ontario Tumor bank (OTB) of the Ontario Cancer Research Institute (OICR), (a repository of tumor tissues created on the basis donor consent), following approval of human ethics by the Ethics Review Board of the OICR.

Consent for publication

Not applicable. No personal data is included in this manuscript.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Anatomy and Cell Biology, University of Western Ontario, London, Ontario N6A5C1, Canada. ²Department of Biology, Brandon University, Brandon, Manitoba R7A6A9, Canada. ³Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario N6A5C1, Canada. ⁴Department of Oncology, University of Western Ontario, London, Ontario N6A5C1, Canada.

Received: 15 February 2019 Accepted: 29 May 2019 Published online: 11 June 2019

References

- Howe LR. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res. 2007;9(4):210.
- Rozic JG, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer. 2001;93(4):497–506.
- Timoshenko AV, Xu G, Chakrabarti S, Lala PK, Chakraborty C. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res. 2003;289(2):265–74.
- Timoshenko AV, Chakraborty C, Wagner GF, Lala PK. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer. 2006;94(8):1154–63.
- Xin X, Majumder M, Girish GV, Mohindra V, Maruyama T, Lala PK. Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Investig. 2012;92(8):1115–28.

- Majumder M, Xin X, Liu L, Tutunea-Fatan E, Rodriguez-Torres M, Vincent K, et al. COX-2 induces breast Cancer stem cells via EP4/PI3K/AKT/NOTCH/ WNT Axis. Stem Cells. 2016;34(9):2290–305.
- Park TS, Donnenberg VS, Donnenberg AD, Zambidis ET, Zimmerlin L. Dynamic interactions between Cancer stem cells and their stromal partners. Curr Pathobiol Rep. 2014;2(1):41–52.
- Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea--a paradigm shift. Cancer Res. 2006;66(4):1883–90.
- Kim Y, Joo KM, Jin J, Nam D-H. Cancer stem cells and their mechanism of chemoradiation resistance. International Journal of Stem Cells. 2009;2(2):109–14.
- Majumder M, Nandi P, Omar A, Ugwuagbo KC, Lala PK. EP4 as a therapeutic target for aggressive human breast Cancer. Int J Mol Sci 2018; 19(4). doi: 10. 3390/ijms19041019.
- Majumder M, Landman E, Liu L, Hess D, Lala PK. COX-2 elevates oncogenic miR-526b in breast Cancer by EP4 activation. Mol Cancer Res. 2015;13(6):1022–33.
- Majumder M, Dunn L, Liu L, Hasan A, Vincent K, Brackstone M, et al. COX-2 induces oncogenic micro RNA miR655 in human breast cancer. Sci Rep. 2018;8(1):327. https://doi.org/10.1038/s41598-017-18612-3.
- 13. Sassen S, Miska EA, Caldas C. MicroRNA: implications for cancer. Virchows Arch. 2008;452(1):1–10.
- 14. Fernández-Miranda G, Méndez R. The CPEB-family of proteins, translational control in senescence and cancer. Ageing Res Rev. 2012;11(4):460–72.
- Paris J, Richter JD. Maturation-specific polyadenylation and translational control: diversity of cytoplasmic polyadenylation elements, influence of poly (a) tail size, and formation of stable polyadenylation complexes. Mol Cell Biol. 1990;10(11):5634–45.
- Wakiyama M, Imataka H, Sonenberg N. Interaction of elF4G with poly(a)binding protein stimulates translation and is critical for Xenopus oocyte maturation. Curr Biol. 2000;10(18):1147–50.
- Nagaoka K, Fujii K, Zhang H, Usuda K, Watanabe G, Ivshina M, et al. CPEB1 mediates epithelial-to-mesenchyme transition and breast cancer metastasis. Oncogene. 2016;35(22):2893–901.
- Galardi S, Petretich M, Pinna G, D'Amico S, Loreni F, Michienzi A, et al. CPEB1 restrains proliferation of glioblastoma cells through the regulation of p27 (Kip1) mRNA translation. Sci Rep. 2016;6:25219. https://doi.org/10.1038/srep25219.
- Zou CD, Zhao WM, Wang XN, Li Q, Huang H, Cheng WP, et al. MicroRNA-107: a novel promoter of tumor progression that targets the CPEB3/EGFR axis in human hepatocellular carcinoma. Oncotarget. 2016;7(1):266–78.
- Foundation KAW. The human protein atlas project 2005 [updated 2018-11-15. Available from: https://www.proteinatlas.org/ENSG00000107864-CPEB3/pathology.
- Tian Q, Liang L, Ding J, Zha R, Shi H, Wang Q, et al. MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation elementbinding protein 4 in hepatocellular carcinoma. PLoS One. 2012;7(11):e48958.
- Ortiz-Zapater E, Pineda D, Martinez-Bosch N, Fernandez-Miranda G, Iglesias M, Alameda F, et al. Key contribution of CPEB4-mediated translational control to cancer progression. Nat Med. 2011;18(1):83–90.
- Cao G, Chen D, Liu G, Pan Y, Liu Q. CPEB4 promotes growth and metastasis of gastric cancer cells via ZEB1-mediated epithelial- mesenchymal transition. Onco Targets Ther. 2018;11:6153–65.
- Hagele S, Kuhn U, Boning M, Katschinski DM. Cytoplasmic polyadenylationelement-binding protein (CPEB)1 and 2 bind to the HIF-1alpha mRNA 3'-UTR and modulate HIF-1alpha protein expression. Biochem J. 2009;417(1):235–46.
- 25. Chen PJ, Huang YS. CPEB2-eEF2 interaction impedes HIF-1alpha RNA translation. EMBO J. 2012;31(4):959–71.
- 26. Ajduković J. HIF-1-a big chapter in the cancer tale. Exp Oncol. 2016;38(1):9-12.
- Nairismagi ML, Vislovukh A, Meng Q, Kratassiouk G, Beldiman C, Petretich M, et al. Translational control of TWIST1 expression in MCF-10A cell lines recapitulating breast cancer progression. Oncogene. 2012;31(47):4960–6.
- Lam CS, Ng L, Chow AK, Wan TM, Yau S, Cheng NS, et al. Identification of microRNA 885-5p as a novel regulator of tumor metastasis by targeting CPEB2 in colorectal cancer. Oncotarget. 2017;8(16):26858–70.
- Johnson RM, Vu NT, Griffin BP, Gentry AE, Archer KJ, Chalfant CE, et al. The alternative splicing of cytoplasmic polyadenylation element binding protein 2 drives Anoikis resistance and the metastasis of triple negative breast Cancer. J Biol Chem. 2015;290(42):25717–27.
- DeLigio JT, Lin G, Chalfant CE, Park MA. Splice variants of cytosolic polyadenylation element-binding protein 2 (CPEB2) differentially regulate pathways linked to cancer metastasis. J Biol Chem. 2017;292(43):17909–18.
- Qu Y, Han B, Yu Y, Yao W, Bose S, Karlan BY, et al. Evaluation of MCF10A as a reliable model for Normal human mammary epithelial cells. PLoS One. 2015;10(7):e0131285.

- Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell. 2013;154(6):1380–9.
- Gandin V, Sikstrom K, Alain T, Morita M, McLaughlan S, Larsson O, et al. Polysome fractionation and analysis of mammalian translatomes on a genome-wide scale. J Vis Exp. 2014;(87). https://doi.org/10.3791/51455.
- Kim NG, Koh E, Chen X, Gumbiner BM. E-cadherin mediates contact inhibition of proliferation through hippo signaling-pathway components. Proc Natl Acad Sci U S A. 2011;108(29):11930–5.
- Kourtidis A, Lu R, Pence LJ, Anastasiadis PZ. A central role for cadherin signaling in cancer. Exp Cell Res. 2017;358(1):78–85.
- Liu CY, Lin HH, Tang MJ, Wang YK. Vimentin contributes to epithelialmesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation. Oncotarget. 2015;6(18):15966–83.
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
- Burns DM, Richter JD. CPEB regulation of human cellular senescence, energy metabolism, and p53 mRNA translation. Genes Dev. 2008;22(24):3449–60.
- 39. Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 2007;19(2):150–8.
- Turimella SL, Bedner P, Skubal M, Vangoor VR, Kaczmarczyk L, Karl K, et al. Characterization of cytoplasmic polyadenylation element binding 2 protein expression and its RNA binding activity. Hippocampus. 2015;25(5):630–42.
- Hurst DR, Xie Y, Edmonds MD, Welch DR. Multiple forms of BRMS1 are differentially expressed in the MCF10 isogenic breast cancer progression model. Clin Exp Metastasis. 2009;26(2):89–96.
- Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993;7(5):812–21.
- Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–8.
- Chen A, Beetham H, Black MA, Priya R, Telford BJ, Guest J, et al. E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition. BMC Cancer. 2014;14:552. https://doi.org/10.1186/1471-2407-14-552.
- Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR. Cadherin switching. J Cell Sci. 2008;121(Pt 6:727–35.
- Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA. Exogenous expression of N-cadherin in breast Cancer cells induces cell migration, invasion, and metastasis. J Cell Biol. 2000;148(4):779–90.
- Alexander NR, Tran NL, Rekapally H, Summers CE, Glackin C, Heimark RL. Ncadherin gene expression in prostate carcinoma is modulated by integrindependent nuclear translocation of Twist1. Cancer Res. 2006;66(7):3365–9.
- Li J, Zhou BP. Activation of beta-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer. 2011;11:49. https://doi.org/10.1186/1471-2407-11-49.
- Maestro R, Tos APD, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev. 1999;13(17):2207–17.
- Smit MA, Peeper DS. Epithelial-mesenchymal transition and senescence: two cancer-related processes are crossing paths. Aging (Albany NY). 2010;2(10):735–41.
- Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000;2(2):84–9.
- 52. Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer. 2014;14(5):359–70.
- Lee HK, Jeong S. Beta-catenin stabilizes cyclooxygenase-2 mRNA by interacting with AU-rich elements of 3'-UTR. Nucleic Acids Res. 2006;34(19): 5705–14 Epub 2006 Oct 12.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- · thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions



Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH ("Springer Nature").

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users ("Users"), for smallscale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use ("Terms"). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

- 1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
- 2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
- 3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
- 4. use bots or other automated methods to access the content or redirect messages
- 5. override any security feature or exclusionary protocol; or
- 6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

onlineservice@springernature.com